Fundz

Novalis Invests in Enzyre to Support Development of Enzypad, a Breakthrough Hand-Held Diagnostic and Monitoring Device

PRIVATEJul 27, 2020

Round Type

Funding Round

NijmegenBiotechnologyHealth CareMedical

Description

Enzyre, a developer of breakthrough diagnostic technology to bring the lab to the patient, announced today that Novalis Biotechnology Incubation, through its seed fund, participated as co-financer in the Euro 1.4 million Corona Bridge Loan granted by the Dutch government in support of innovative start-ups and scale-ups.

Who else raised in Medical and Biotechnology around the same time

Companies in the same sectors as Enzyre that raised within 45 days of this round, from Fundz verified event records.

  • Monteris Medical raised $9M on September 4, 2020.
  • ORTHALIGN INC raised $11M on September 2, 2020.
  • WaveFront Dynamics Inc. raised $833K (Seed) on September 1, 2020.
  • Optimize Systems raised $15M on August 28, 2020.
  • NeuroOne Medical Technologies Corporation raised $135K (Seed) on August 10, 2020.
  • enVVeno Medical raised $1.6M (Seed) on August 4, 2020.

Who to call at Enzyre, and when

A new round usually means Enzyre is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Enzyre raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Enzyre, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Enzyre. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Enzyre

Location

Nijmegen, Gelderland, Netherlands

About

Enzyre is a spin-out from Radboud University Medical Center in The Netherlands founded by Waander van Heerde and Guido Maertens. The Company aims to develop a diagnostic device to provide patients with the flexibility to assess their coagulation status regardless of where they are. Enzyre's platform requires a small volume of blood to measure up to sixteen reactions simultaneously with high sensitivity and specificity without any laboratory infrastructure, at home, on the road or in a critical care setting. This offers enormous benefits to patients: avoid crisis situations driven by changes in coagulation status, provide ease of mind for patients, empower patients to optimize treatment themselves, be a quick turnaround tool in the clinical setting, reduce GP consultation visits and, as a personalized diagnostic tool, offer great support in a telemedicine setting.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Enzyre raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Enzyre's next move

See what Strategic adds

Enzyre raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.